NASDAQ:REGN - Regeneron Pharmaceuticals Stock Price, Forecast & News

Regeneron Pharmaceuticals' stock was trading at $464.70 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, REGN shares have decreased by 3.3% and is now trading at $449.52. View which stocks have been mosted impacted by Coronavirus.

23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 10 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) issued its earnings results on Thursday, February, 6th. The biopharmaceutical company reported $7.50 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $6.03 by $1.47. The biopharmaceutical company earned $2.17 billion during the quarter, compared to analysts' expectations of $2.10 billion. Regeneron Pharmaceuticals had a return on equity of 24.14% and a net margin of 26.91%. The firm's revenue for the quarter was up 12.6% on a year-over-year basis. During the same period last year, the company earned $6.84 earnings per share. View Regeneron Pharmaceuticals' earnings history.

Regeneron Pharmaceuticals announced that its Board of Directors has initiated a share buyback program on Tuesday, November 5th 2019, which allows the company to buyback $1,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to reacquire up to 2.9% of its stock through open market purchases. Stock buyback programs are usually an indication that the company's management believes its shares are undervalued.

23 brokers have issued 1-year price objectives for Regeneron Pharmaceuticals' shares. Their forecasts range from $325.00 to $550.00. On average, they anticipate Regeneron Pharmaceuticals' stock price to reach $460.13 in the next year. This suggests a possible upside of 2.4% from the stock's current price. View analysts' price targets for Regeneron Pharmaceuticals.

News stories about REGN stock have trended very positive recently, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Regeneron Pharmaceuticals earned a news impact score of 4.0 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutRegeneron Pharmaceuticals.

Regeneron Pharmaceuticals saw a decrease in short interest in March. As of March 13th, there was short interest totaling 2,558,900 shares, a decrease of 11.1% from the February 27th total of 2,880,000 shares. Based on an average daily volume of 1,294,900 shares, the days-to-cover ratio is presently 2.0 days. Approximately 3.1% of the company's stock are short sold. View Regeneron Pharmaceuticals' Current Options Chain.

Some companies that are related to Regeneron Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Exelixis (EXEL) and Repligen (RGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include Netflix (NFLX), Gilead Sciences (GILD), Biogen (BIIB), NVIDIA (NVDA), Alibaba Group (BABA), Celgene (CELG), Tesla (TSLA), Alphabet (GOOG), Micron Technology (MU) and Broadcom (AVGO).

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Regeneron Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Capital World Investors (7.57%), Loomis Sayles & Co. L P (3.36%), State Street Corp (3.26%), FMR LLC (2.94%), Alliancebernstein L.P. (1.77%) and Polen Capital Management LLC (1.53%). Company insiders that own Regeneron Pharmaceuticals stock include Andrew J Murphy, Christopher R Fenimore, George L Sing, Joseph L Goldstein, Michael S Brown, Neil Stahl, P Roy Vagelos, Robert E Landry and Sanofi. View institutional ownership trends for Regeneron Pharmaceuticals.

REGN stock was sold by a variety of institutional investors in the last quarter, including Parnassus Investments CA, Janus Henderson Group PLC, Alliancebernstein L.P., Renaissance Technologies LLC, Rockefeller Capital Management L.P., Sustainable Growth Advisers LP, Pictet Asset Management Ltd., and Russell Investments Group Ltd.. Company insiders that have sold Regeneron Pharmaceuticals company stock in the last year include Andrew J Murphy, Christopher R Fenimore, George L Sing, Joseph L Goldstein, Michael S Brown, Neil Stahl, P Roy Vagelos, Robert E Landry, and Sanofi. View insider buying and selling activity for Regeneron Pharmaceuticals.

REGN stock was bought by a variety of institutional investors in the last quarter, including Norges Bank, Nuveen Asset Management LLC, FMR LLC, LSV Asset Management, Capital World Investors, Krensavage Asset Management LLC, Skandinaviska Enskilda Banken AB publ, and Loomis Sayles & Co. L P. View insider buying and selling activity for Regeneron Pharmaceuticals.

Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of REGN stock can currently be purchased for approximately $449.52.

Regeneron Pharmaceuticals has a market capitalization of $49.46 billion and generates $7.86 billion in revenue each year. The biopharmaceutical company earns $2.12 billion in net income (profit) each year or $21.47 on an earnings per share basis. Regeneron Pharmaceuticals employs 8,100 workers across the globe. View additional information about Regeneron Pharmaceuticals.

The official website for Regeneron Pharmaceuticals is http://www.regeneron.com/.

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company can be reached via phone at 914-847-7000 or via email at [email protected]